Danaher (DHR) has moved back into focus after the company announced that Julie Sawyer Montgomery will become President and CEO on October 1, 2026, as long-time leader Rainer Blair retires.
See our latest analysis for Danaher.
Danaher shares now trade at US$197.50, with a 90 day share price return of 12.91% contrasting with a year to date share price decline of 14.28%. The 1 year total shareholder return is broadly flat and the 5 year total shareholder return is down 26.08%. This points to recent momentum improving after a tougher multi year stretch as investors react to earnings, guidance and the leadership transition.
If this leadership change has you reviewing your watchlist, it can be a good moment to look at other healthcare focused opportunities and scan the 41 healthcare AI stocks
Bulls see Danaher’s recent earnings progress and boardroom continuity as support for the higher share price. Bears point to mixed multi year returns and trimmed growth guidance. Which case lines up better with today’s valuation?
Most Popular Narrative: 14% Undervalued
At a last close of $197.50 versus a narrative fair value around $228.61, Danaher screens as undervalued on this widely followed long term view, which leans heavily on recurring healthcare revenue and margin resilience.
The sustained advancement of precision medicine and personalized therapies, including new AI-assisted diagnostic solutions and groundbreaking launches in genomics (like support for in vivo CRISPR therapies), positions Danaher's technology portfolio to capture higher-margin growth and drive long-term EBITDA expansion.
Want to see what is embedded in that fair value for Danaher? The narrative leans on recurring consumables, rising profitability and a future earnings multiple that still steps down from today.
Result: Fair Value of $228.61 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Danaher’s reliance on bioprocessing demand and its exposure to changing healthcare policies in markets like China could still unsettle that undervalued narrative if conditions worsen.
Find out about the key risks to this Danaher narrative.
Next Steps
With mixed signals around Danaher, are you leaning more toward the bull or the bear case, and how quickly do you want to firm up your view? To see the full picture of potential upsides and concerns, check out the 3 key rewards and 1 important warning sign
Looking for more investment ideas beyond Danaher?
If Danaher has sharpened your appetite for opportunities, do not stop here. Use the Simply Wall Street Screener to compare different angles and refine your watchlist.
- Target potential value opportunities by checking companies that line up in the 53 high quality undervalued stocks.
- Prioritise financial strength by reviewing stocks in the solid balance sheet and fundamentals stocks screener (46 results).
- Hunt for promising out of favour stories using the screener containing 18 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com